Answers are grounded in this paper and cite their sources.
This study aimed to investigate the expression pattern of FAM83A in primary breast cancer tissues and its association with clinicopathological characteristics, including lymph node metastasis. A total of 70 breast cancer specimens and 20 paired adjacent normal tissue samples were collected, FAM83A expression was examined in primary breast cancer tissues. Patients were subsequently divided into two groups based on their lymph node metastasis status: N0 (without lymph node metastasis) and N+ (with lymph node metastasis). The association between FAM83A expression in primary tumors and lymph node metastasis status was then analyzed.Immunohistochemistry was performed to assess the expression level of FAM83A in all collected tissues. Of the 70 breast cancer cases, 61 (87.1%) were positive for FAM83A expression, whereas no or weak staining was observed in adjacent normal tissues. FAM83A positivity was observed in 89.5% (34/38) of patients without lymph node metastasis and 84.4% (27/32) of those with lymph node metastasis, with no statistically significant difference between the two groups ( P = 0.529). FAM83A expression was significantly associated with estrogen receptor (ER) status ( P = 0.007), but not with age, T stage, or lymph node metastasis. FAM83A is highly expressed in breast cancer tissues and is associated with ER status, suggesting its potential as a candidate biomarker for breast cancer. However, its expression was not significantly correlated with lymph node metastasis in this cohort. Further functional studies are warranted to elucidate the biological role of FAM83A in breast cancer pathogenesis.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: